<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00712686</url>
  </required_header>
  <id_info>
    <org_study_id>CN138-003</org_study_id>
    <nct_id>NCT00712686</nct_id>
  </id_info>
  <brief_title>Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and tolerability of aripiprazole to
      olanzapine over 26 weeks for the treatment of schizophrenia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean change in the PANSS Total Score</measure>
    <time_frame>from baseline to Week 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of patients showing significant weight gain (a≥ 7% increase)</measure>
    <time_frame>from baseline to Week 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on the CGI-S Score</measure>
    <time_frame>at the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on PANSS Total Score</measure>
    <time_frame>at the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on PANSS-Positive Scale Total Score</measure>
    <time_frame>at the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on PANSS-Negative Scale Total Score</measure>
    <time_frame>at the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in PANSS-derived Brief Psychiatric Rating Scale (BPRS) Core Score</measure>
    <time_frame>at the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean CGI-I Score</measure>
    <time_frame>at the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders (≥ 30% decrease in PANSS Total Score, or score of 1 or 2 on CGI-I)</measure>
    <time_frame>at the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on the MADRS</measure>
    <time_frame>at the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>at the end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">690</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>A1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Tablets, Oral, 15-30 mg, once daily, 140 weeks</description>
    <arm_group_label>A1</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Capsule, Oral, 10-20 mg, once daily, 140 weeks</description>
    <arm_group_label>B1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with DSM-IV diagnosis of schizophrenia patients in acute relapse

          -  Treated as outpatients for at least one continuous 3-month period during the past 12
             months

          -  PANSS total score ≥60

          -  Previously responsive to neuroleptics (other than clozapine)

          -  Able to give informed consent and comprehend and satisfactorily comply with the
             protocol requirements

        Exclusion Criteria:

          -  An Axis I (DSM-IV) diagnosis of schizoaffective disorder

          -  A clinical picture and/or history that was consistent with: (a) Delirium, dementia,
             amnestic or other cognitive disorders; (b) Bipolar disorder; (c)personality disorder

          -  Nonresponsive to prior olanzapine therapy

          -  Likely to require prohibited concomitant therapy

          -  DSM-IV criteria for any significant substance abuse within the past three months,
             including addiction to cocaine or alcohol

          -  Known to be allergic or hypersensitive to study drugs

          -  Represented a significant risk of committing suicide based on history or mental status
             exam

          -  Unstable thyroid pathology and treatment within the past six months

          -  A history or evidence of a medical condition that would expose the patient to an undue
             risk

          -  Clinically significant abnormal laboratory test results (including urine drug screen),
             vital sign, or ECG findings
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <reference>
    <citation>Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009 Mar 15;65(6):510-7. doi: 10.1016/j.biopsych.2008.07.033. Epub 2008 Nov 4.</citation>
    <PMID>18986646</PMID>
  </reference>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2008</study_first_submitted>
  <study_first_submitted_qc>July 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2008</study_first_posted>
  <last_update_submitted>November 7, 2013</last_update_submitted>
  <last_update_submitted_qc>November 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2013</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

